Delavirdine

Drug Profile

Delavirdine

Alternative Names: Delavirdine mesylate; Rescriptor; U 90152T; U-90152-S

Latest Information Update: 07 Jul 2010

Price : $50

At a glance

  • Originator Pfizer
  • Developer Daiichi Sankyo Company; Pfizer
  • Class Antiretrovirals; Indoles; Piperazines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 07 Jul 2010 Development discontinued in the European Union before 2001
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top